IgA Nephropathy Epidemiology

Sep 16, 2024

A year after failing to meet a trial endpoint, Travere Therapeutics can now relax. On 05 September 2024, the FDA upgraded FILSPARI’s conditional approval for the kidney disease IgA nephropathy to full approval. FILSPARI’s complete approval broadens its use, permitting the small molecule blocker to help slow kidn...

Jul 22, 2024

Conventional  IgA nephropathy treatments include ACE inhibitors (angiotensin-converting enzyme inhibitors) and ARBs (angiotensin II receptor blockers) to manage symptoms like high blood pressure. The only two FDA-approved treatments for managing IgAN are TARPEYO/KINPEYGO (budesonide) and FILSPARI (sparsentan)....

Nov 05, 2021

IgA Nephropathy (IgAN), also called Berger’s disease, is an autoimmune rare disease affecting the kidneys. It impairs blood filtration in the kidneys' tiny blood channels. An aberrant protein destroys the filtering unit (glomerulus) inside the kidneys, causing IgA Nephropathy. It is estimated that 20–40% of persons...

Sep 24, 2021

Chronic diseases (CDs) pose a significant challenge to healthcare in the 21st century. Factors such as population aging, lifestyle-modifiable risk factors, a decline in early-life infectious diseases, sedentary lifestyle, unhealthy food habits have resulted in the emergence of chronic diseases as a major global hea...